Pembrolizumab-induced thyroiditis in gynecologic oncology: A comprehensive review

Read full text Summarise with VIRAT
Authors: Nadia Syed, Meghana Kanaparthi, Hema Dovari, Atufa Juveriya Mohammad, Dhanush Bellapu, Padmalatha Kantamaneni
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pembrolizumab is a programmed cell death-1 (PD-1) immune checkpoint inhibitor that has shown significant clinical benefits for several gynecologic cancers, including cervical, endometrial, and ovarian cancers. While it offers therapeutic benefits, pembrolizumab is linked to immune-related adverse events (Irae's), particularly affecting the endocrine system. Thyroid dysfunction, commonly known as thyroiditis, is the main endocrine complication. Pembrolizumab-induced thyroiditis typically follows a biphasic pattern. It starts with temporary thyrotoxicosis and can progress to hypothyroidism, which may become permanent. This review provides an updated, original overview of the mechanisms, clinical features, diagnosis, monitoring, and management of pembrolizumab-induced thyroiditis, focusing on its importance in gynecologic oncology practice.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Thyroid Disorders and Treatments Thyroid Cancer Diagnosis and Treatment

Publication details

Journal / source
International Journal of Pharmacology and Clinical Research
Volume
8
Issue
2
Pages
49–54
Publication date
1 February 2026
Language
EN